[250 Pages Report] The global IVD antibodies market is projected to grow at a healthy CAGR of around 3.8% during the forecast period between 2022 and 2032, reaching a valuation of nearly US$ 1.38 Billion by 2022. Demand for IVD antibodies is driven by the rising prevalence of chronic and infectious diseases worldwide and the increasing need for early diagnosis of chronic diseases to initiate proper treatment.
| Report Attribute | Details |
|---|---|
| IVD Antibodies Market Estimated Growth Rate (2022 to 2032) | 3.8% CAGR |
| IVD Antibodies Market Projected Size (2032) | US$ 2 Billion |
As the global burden of chronic and infectious diseases continues to escalate, medical professionals and researchers are looking for innovative techniques and technologies to diagnose diseases at their early stages. This has put the in-vitro diagnostic (IVD) antibodies market into the spotlight.
IVD antibodies are unique diagnostic tools used for clinical diagnostics and research applications. They have become a critical component of many diagnostic assays used to detect and diagnose numerous chronic and infectious diseases such as cancer, tuberculosis, HIV etc. These IVD antibodies help medical professionals to detect and diagnose diseases at early stages, thereby allowing them to initiate proper treatment approaches.
In recent years, demand for IVD antibodies has risen at a robust pace due to increasing popularity of immunology methods such as sandwich ELISA and immunonephelometry and this trend is likely to continue during the forecast period.
Consequently, increasing proteomics and genomics research activities along with rising consumer inclinations towards opting for novel diagnostic techniques will create space for IVD antibodies market growth in the future.
By applications, FMI predicts that the cancer segment will continue to dominate the global IVD antibodies market due to the increasing incidence of cancer and a rise in cancer diagnostic screening.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing incidence of chronic and infectious diseases such as HIV, hepatitis, cancer, cardiovascular diseases, malaria, hepatitis, etc., across the world is a major factor driving the growth in IVD antibodies market and the trend is likely to continue during the forecast period.
IVD antibodies have become highly sought-after diagnostic products used across diagnostic laboratories and hospitals for early and accurate detection of diseases like Cancer. Thus, rapid surge in cases of various types of cancer globally will eventually boost the growth of IVD antibodies market during the forecast period.
As per the American Cancer Society, the global cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. This will create immense opportunities for IVD antibodies manufacturers during the forthcoming years.
Similarly, increasing research and development coupled with rising investments by government and non-government organizations in medical research field is likely to expand the IVD antibodies market size.
Furthermore, growing popularity of home healthcare and presence of user-friendly antibodies-based diagnostic products will further boost the demand for IVD antibodies in future.
There is no doubt that IVD antibodies have become highly-sought after diagnostic products used across healthcare facilities such as hospitals and diagnostic laboratories. However, there are some factors that are challenging the growth of IVD antibodies market. These factors include higher cost of the IVD antibodies, low product penetration, and lack of adequate healthcare facilities across lower economies.
Similarly, time consuming nature of research and development along with lengthy product approval process is negatively impacting market growth.
Principal Consultant
According to Future Market Insights, North America will continue to dominate the global antibodies market during the forecast period between 2022 and 2032. Growth in North America IVD antibodies market is driven by increasing drug research and development activities, higher product penetration, rising prevalence of cancer and cardiovascular diseases, availability of favorable reimbursement policies, and presence of leading IVD antibodies manufacturers.
Demand for IVD antibodies is especially rising across the U.S. due to surge in cancer cases, availability of highly advanced healthcare industry, increasing investments in research and development activities, and presence of leading pharmaceutical and biopharmaceutical giants.
The U.S. is home to one of the largest healthcare industries in the world. The country spends billions of dollars annually on medical research and drug development activities. For instance, annually the National Institutes of Health (NIH) alone spends around US$ 41.7 billion in medical research for the American people. This is creating a conducive environment for the growth of IVD antibodies market in the region.
Similarly, growing popularity of point of care diagnostic will support the growth of IVD antibodies market during the forecast period.
Demand for IVD antibodies is anticipated to rise at a substantial pace across Europe during the forecast period, owing to the rising prevalence of various chronic and infectious diseases, surge in diagnostic procedures, increasing government support, and rapid expansion of healthcare industry.
Rising prevalence of cancer and other chronic diseases across countries like the U.K. and Germany due to factors such as excessive drinking and smoking, exposure to harmful radiations, and rapidly growing geriatric populations is fueling the demand for IVD antibodies.
According to Cancer Research UK, each year more than a third (36%) of all cancer cases in the UK are diagnosed in people aged 75 and over. Thus, rise in cancer cases due to increasing geriatric population will continue to play a key role in augmenting the growth of IVD antibodies market in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the leading manufacturers of IVD antibodies include Thermo Fisher Scientific, Rockland Immunochemicals Inc., Abcam plc., SDIX, LLC., GenScript, Bio-Rad Laboratories, Inc., HyTest Ltd., Biocare Medical, Advy Chemical Pvt. Ltd., MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., and Abbott among others.
These leading players are rigorously investing in research and development to expand their product portfolios. Moreover, they have adopted various strategies such as new product launches and approvals, partnerships, collaborations, acquisitions, etc. to capitalize on the emerging opportunities and get a competitive edge in the market.
Companies like Biocare Medical, Thermo fisher Scientific, Bio-Rad Laboratories and Abcam plc. are likely to hold a significant share of the global IVD antibodies market through 2032. These players are continuously introducing new products to expand their portfolios and cater to the rising end user demands. For instance, in 2020 Biocare Medical launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 3.8% from 2022 to 2032 |
| Projected Market Size (2032) | 2 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
As per FMI, demand in the global IVD antibodies market is expected to grow at around 7% CAGR during the forecast period.
North America is expected to continue its dominance in the global IVD antibodies market during the forecast period.
Thermo Fisher Scientific, Rockland Immunochemicals Inc., Abcam plc., SDIX, LLC., GenScript, Bio-Rad Laboratories, Inc., HyTest Ltd., Advy Chemical Pvt. Ltd., MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., and Abbott are some of the leading players operating in IVD antibodies market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. Value Chain Analysis 3.5.1. Profit Margin Analysis 3.5.2. Service Providers 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global IVD Antibodies Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2022-2032 5.3.1. Cardiac Markers 5.3.2. Tumor Markers 5.3.3. Kidney Injury Markers 5.3.4. Infection and Inflammation Antibodies 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032 6. Global IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032 6.3.1. Immunology 6.3.2. Cancer 6.3.3. Cardiovascular Diseases 6.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021 6.5. Absolute $ Opportunity Analysis By Application, 2022-2032 7. Global IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals 7.3.2. Diagnostic Laboratories 7.3.3. Homecare Settings 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 8. Global IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. MEA 8.4. Market Attractiveness Analysis By Region 9. North America IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Product Type 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Type 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Mexico 10.2.1.2. Brazil 10.2.1.3. Rest of Latin America 10.2.2. By Product Type 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Europe IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Spain 11.2.1.6. BENELUX 11.2.1.7. Russia 11.2.1.8. Rest of Europe 11.2.2. By Product Type 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. East Asia IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Product Type 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. South Asia & Pacific IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. ASEAN 13.2.1.3. Australia and New Zealand 13.2.1.4. Rest of South Asia & Pacific 13.2.2. By Product Type 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. MEA IVD Antibodies Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. Turkey 14.2.1.3. South Africa 14.2.1.4. Rest of MEA 14.2.2. By Product Type 14.2.3. By Application 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. By Application 14.3.4. By End User 14.4. Key Takeaways 15. Key Countries IVD Antibodies Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Product Type 15.1.2.2. By Application 15.1.2.3. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Product Type 15.2.2.2. By Application 15.2.2.3. By End User 15.3. Mexico 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Product Type 15.3.2.2. By Application 15.3.2.3. By End User 15.4. Brazil 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Product Type 15.4.2.2. By Application 15.4.2.3. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Product Type 15.5.2.2. By Application 15.5.2.3. By End User 15.6. Italy 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Product Type 15.6.2.2. By Application 15.6.2.3. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Product Type 15.7.2.2. By Application 15.7.2.3. By End User 15.8. U.K. 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Product Type 15.8.2.2. By Application 15.8.2.3. By End User 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Product Type 15.9.2.2. By Application 15.9.2.3. By End User 15.10. BENELUX 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Product Type 15.10.2.2. By Application 15.10.2.3. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Product Type 15.11.2.2. By Application 15.11.2.3. By End User 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Product Type 15.12.2.2. By Application 15.12.2.3. By End User 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Product Type 15.13.2.2. By Application 15.13.2.3. By End User 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Product Type 15.14.2.2. By Application 15.14.2.3. By End User 15.15. India 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Product Type 15.15.2.2. By Application 15.15.2.3. By End User 15.16. ASEAN 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Product Type 15.16.2.2. By Application 15.16.2.3. By End User 15.17. Australia and New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Product Type 15.17.2.2. By Application 15.17.2.3. By End User 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Product Type 15.18.2.2. By Application 15.18.2.3. By End User 15.19. Turkey 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Product Type 15.19.2.2. By Application 15.19.2.3. By End User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Product Type 15.20.2.2. By Application 15.20.2.3. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product Type 16.3.3. By Application 16.3.4. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Abcam plc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Thermo Fisher Scientific 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Rockland Immunochemicals Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. GenScript 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Bio-Rad Laboratories, Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. SDIX, LLC. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Advy Chemical Pvt. Ltd. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. HyTest Ltd 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Abbott 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
IVD Antibodies Market
